进展期胃癌术式选择及术中腹腔化疗探析

张高嘉; 郭建生; 王仆; 郝希山

进展期胃癌术式选择及术中腹腔化疗探析

津市肿瘤防治重点实验室天津医科大学附属肿瘤医院综合外科, 天津市 300060

详细信息

通讯作者:
张高嘉,E-mail:sxj@yahoo.com.cn

中图分类号: R735.2
计量
- 文章访问数: 2
- HTML全文浏览量: 0
- PDF下载量: 1
出版历程
- 修回日期: 2008-08-19
- 发布日期: 2008-11-29

Surgical Procedure Selection and Intraoperative Intra-abdominal Chemotherapy for Patients with Advanced Gastric Cancer

Department of Surgery, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China

摘要

摘要: 阐述晚期胃癌TNMⅣ期,其复发形式多见于腹膜播散性转移和种植,并影响预后之重要因素。即使进行根治术,亦仅称之为非治疗性切除术。进展期胃癌进行广泛淋巴清扫价值始终存在分歧和争议。侵出浆膜之患者其五年治疗率低下。肉眼腹膜种植者,腹腔游离癌细胞近乎100%。伴随侵出面积增大,其治疗率而降低。肿瘤标志物监测诸如TPA,CA724,CA242,CA199以及CEA等,睿智据理规范和启迪术式及术中化疗之实施,选定多元化特异性高的标志物检测,可提高敏感性,皆阳性者则诊断无疑。临床残留癌细胞是客观存在,术中第一时间强烈干预腹腔内置入抗癌药物为最理想。诸如MMC-CH,CDDP,Vp16以及区域性缓释化疗抗肿瘤植入剂Sinofuan等不乏为首选。晚期胃癌循规蹈矩进行D2或D3术式,难以达到期望阈值。D2术式不能提高患者生存率。D1,D2术式术后生存率统计学上分析无明显差异。淋巴清扫仅有助于病理分期确切性,偏倚扩大根治术,善其予后难以期待。
- 晚期胃癌 /
- 肿瘤标志物 /
- 术中腹腔化疗
Abstract: Peritoneal dissemination is commonly found in stage 4 gastric cancer patients and it is a key factor inthe prognosis of advanced gastric cancer. Radical resection for gastric cancer is still controversial and is con-sidered a palliative procedure. In patients with tumors penetrating through the serosa, the 5-year survival rateis low. Isolated cancer cells almost always exist when peritoneal metastasis is detectable by the naked eye.Patients with more tumor invasion out of the stomach have a lower survival rate. Combined use of biomarkersTPA, CA242, CA212, CA199, and CEA can increase the sensitivity of diagnosis. When residual tumor is clini-cally confirmed, intraoperative peritoneal chemotherapy should be administered. Anti-cancer agents such as MMC-CH, CDDP, VP-16 and controlled-release Sinofuan can be used. For patients with advanced gastriccancer, it is hard to predict the outcome of traditional D2 or D3 radical resection. D2 resection does not in-crease patient survival. No statistical significance was found in survival rates between D1 and D2 resection.Lymph node resection is only helpful for the identification of precise pathological staging. Expanded radical re-section does not improve the survival of patients with advanced gastric cancer.
- Advanced gastric cancer /
- Tumor marker /
- Intraoperative intra-abdominal chemotherapy

HTML全文

参考文献(1)

[1]

1 叶坤辉,安理.胃癌分子标靶治疗药物的新进展[J].临床肿瘤学杂志,2007,12(1):1-10.
2 Glimelius B.Ekström K,et al.Hoffman K.Randomized compari-son between chemotherapy plus best supportive care with bestsupportive care in advanced gastric cancer[J].Ann Oncol,1997,8(2):163-168.
3 Ajani JA.Chemotherapy for gastric carcinoma:new and old op-tions[J].Oncology(Williston Park),1998,12(10 Suppl 7):44-47.
4 饭冢保夫,山村秉彦,镰迪阳.胃癌にぉけゐ腹腔游离癌细胞预后[J].癌の临床,1981,29(15):1808.
5 三轮晃一,北村秀夫,荻野茂.腹腔内游离癌细胞の意义[J],日癌治,1980,6(10):616.
6 刘庆华,陈峻青.胃癌腹腔内游离癌细胞与预后:(附100例临床报告)[J].中国实用外科杂志,1996,16(10):616－617.
7 古贺成昌.再发胃癌の治疗[J].临床外科,1984,39(11):1567.
8 雷哲明,胃癌手术例におけゐ为胃周围おょぴダグラス窝洗涤细胞诊の意义[J],日消外会志,1985,23(3):273.
9 徐惠绵,王剑峰,王振宁.CEAmRNA,CEA蛋白及细胞学检测胃癌腹腔液中游离癌细胞评价[J].中华肿瘤杂志,2000,21(1):45-47.
10 Takahashi T,Hagiwara A,Shimotsuma M,et al.Prophylaxisand treatment of peritoneal carcinomatosis:intraperitonealchemotherapy with mitomycin C bound to activayed carbon par-tiiles[J].World J Surg,1995,19(4):565-569.
11 北村正次,荒井邦佳,岩崎善毅.胃癌の术中腹腔内洗净细胞诊のとセの临床の意义[J].癌的临床,1994,40(3):302-305.
12 饭冢保夫,松井孝夫,广网保明.浆膜癌侵润面积カラ见が胃癌患者の预后[J],癌の临床,1987,23(3):2000-2005.
13 王剑峰,徐惠绵,吴涛.RT-PCR 检测胃癌腹腔液中癌细胞CEAmRNA,MRNA的表达预测腹膜转移的研究[J].中国肿瘤临床,2000,27(7):511-513.
14 シ尺井清司,高桥俊雄,小岛治,进行度にぉじた胃癌治疗の评价と今后の问题点[J].日消外会志,1994,27(4):952-956.
15 朱正纲.应进一步提高胃癌综合治疗的疗效[J].中华胃肠外科杂志,2007,10(5):403-406.
16 李岩.血清胃癌肿瘤标志物的临床价值[J].继续医学教育,2006,20(3):58-62.
17 张伟,王安琼.胃癌术后随诊中CEA和CA(199)联合检测的临床意义[J] 四川肿瘤防治,2004 17(4):229-230.
18 Yoshikawa T,Saitoh M,Tsuburaya A,et al.Tissue inhribitor ofmatrix matalloproteinase-1 in the plasma of patients with gastriccarcinoma.Apossible marker for serosal invasion and metastasis[J].Cancer,1999,86(10):1929-1935.
19 Ubukata H,Katano M,Motohashi G,et al.Evaluation ofCA72-4 as a tumor marker in patients with gastric cancer[J].GanTo Kagaku Ryoho,2003,30(11):1821-1824.
20 小川健治,成高义彦,湖山信笃:胃癌大肠癌における肿瘤マ—カ—の临床の有用性にフぃて进行度の观测[J].癌の临床,1985,3(6):2640.
21 涉谷智彦,山本悟.胃癌症例におけゐTPAの临床の检讨[J].日消外杂志,1984,17(4):236.
22 卢忠,芦加荪.CA199和CA242与胃癌病程发展关系[J].江西医学检测,2003,21(4):253-254.
23 叶颖江,王衫,高志海,等.胃癌和大肠癌患者血清肿瘤标志物联合检验的临床意义[J].中华普通外科杂志,2006,21(4):272-274.
24 Lai IR,Lee WJ,Huang MT,et al.Comparison of serumCA72-4,CEA,TPA,CA19-9 and CA 125 Levels in gastriccarcer patients and correlation with recurrence[J].Hepatogas-troenterology,2002,49(46):1157-1160.
25 Marrelli D,Roviello F,De Stefano A,et al.Prognostic signifi-cance of CEA,CA19-9 and CA72-4 preoperative serum levelsin gastric carcinoma[J].Oncology,1999,57(1):55-61.
26 Takahashi T,Hagiwara A,Ito T.Intraabdominal administrationof MMC adsorbed on activated carbon for management of carci-nomatous peritonitis[J].Gan To Kagaku Ryoho,1984,11(8):1550-1556.
27 谷天理,竹内隆,安岛新一.胃癌におけゐ腹腔内游离癌细胞の活性にフぃて[J].癌の临床,1991,25(2):101-106.
28 平冢正弘,小川明孝,大东弘明.胃癌术后腹膜再发防止を目的とした,mitomycimc腹内大量投入におけゐ投入量安全性[J].日癌志,1998,23(7):1574-1579.
29 Sakakibara T,Ozama T,Ozaki K,et al.Four long-survivingcases of gastric cancer with peritoneal dissemination treated byintraperitoneal administration of mitomycin C adsorbed on acti-vated carbon particles[J].Gan To Kagaku Ryoho,1993,20(11):1700-1702.
30 梁寒,王仆,王晓娜,等.活性碳吸附丝裂霉素C腹腔化疗预防进展期胃癌术后复发[J].中华外科杂志,2003,41(4):274-277.
31 赵海平,欧阳晓辉,孟兴凯.胃癌根治术中腹腔温热化疗结合MMC-CH疗效评价[J].中国肿瘤临床,2006,33(2):84-86.
32 张高嘉,孔大陆,王仆.胃癌浆膜侵出对策之探讨(附100例报告)[J].中国肿瘤临床,2000,27(4):274-275.
33 Bonenkamp JJ,songun I,Hermans J,et al.Randomised compari-son of morbidity after D1 and D2 dissection for gastric cancer in996 Dutch patients[J].Lancet,1995,345(8952):745-748.

施引文献

资源附件(0)

计量

文章访问数: 2
HTML全文浏览量: 0
PDF下载量: 1
被引次数: 0

进展期胃癌术式选择及术中腹腔化疗探析

通讯作者: 张高嘉,E-mail:sxj@yahoo.com.cn

计量

出版历程

Surgical Procedure Selection and Intraoperative Intra-abdominal Chemotherapy for Patients with Advanced Gastric Cancer

计量

出版历程

目录

通讯作者:
张高嘉,E-mail:sxj@yahoo.com.cn